icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
ACH-2684 Demonstrates Potent Viral Suppression in Genotype 1 Hepatitis C Patients With and Without Cirrhosis: Safety, Pharmacokinetic, and Viral Kinetic Analysis
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Eric Lawitz1, John Hill2, Bradley Vince3, Abel Murillo4, Daniel Gruener5,Thomas Marbury6, Michael DeMicco7, Bao Zhang8,Atul Agarwal8, Heather Robison8, Mingjun Huang8, Lisa Robarge8,
James Hui8, Elizabeth Olek8 , Milind Deshpande8, Hetal S. Kocinsky8 1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, DeLand; 3Vince and Associates Clinical Research, Overland Park, KS; 4AMPM Research Clinic, Miami, FL; 5CRI Worldwide, LLC,
Philadelphia, PA; 6Orlando Clinical Research Center, Orlando, FL; 7Anaheim Clinical Trials, Anaheim, CA; 8Achillion Pharmaceuticals, Inc., New Haven, CT

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif